Guanidino-G-Clamp-PNA 

Guanidino-G-Clamp-PNA is a highly efficient sequence-specific RNA binder and gene silencer. Guanidino-G-Clamp-PNA precisely targets such targets as miR-155 or transthyretin (TTR) mRNA through base pairing: the former regulates tumor-related signaling pathways by reducing microRNA activity, while the latter inhibits the translation of harmful proteins via steric hindrance. Guanidino-G-Clamp-PNA effectively stabilizes DNA/RNA duplexes, induces cancer cell apoptosis, and suppresses tumor growth. In addition, Guanidino-G-Clamp-PNA can be conjugated with targeting ligands to improve tissue-specific delivery and reduce in vivo adverse reactions, and it can also enhance the splicing regulation efficacy of other oligonucleotide platforms (such as PMO) when integrated into them. Guanidino-G-Clamp-PNA is applicable to the research of various diseases including diffuse large B-cell lymphoma and hereditary transthyretin-related amyloidosis^[1][2].

Guanidino-G-Clamp-PNA (4 μM cGPNA2; 48 h) inhibits miR-155, upregulates its downstream tumor suppressor targets, and downregulates the expression of oncogenes in U2932 diffuse large B-cell lymphoma cells^[1].
Guanidino-G-Clamp-PNA (4 μM cGPNA2; 48 h) potently inhibits miR-155 and regulates the expression of downstream tumor suppressor genes and oncogenes in SUDHL-5 diffuse large B-cell lymphoma cells^[1].
Guanidino-G-Clamp-PNA (1-4 μM cGPNA5; 24 h) reduces TTR mRNA levels in HepG2 cells in a dose-dependent manner in vitro, achieving a 69% knockdown after treatment with 4 μM for 24 h^[1].
Guanidino-G-Clamp-PNA (0.5-4 μM cGPNA2; 48 h) reduces the viability of U2932 and SUDHL-5 diffuse large B-cell lymphoma cells and induces apoptosis in a dose-dependent manner; after treatment with 4 μM for 48 h, the cell viability decreases by ≥60%, and the proportion of late apoptotic cells in U2932 is approximately 20%^[1].
Guanidino-G-Clamp-PNA (2-4 μM cGPNA5; 3 h) inhibits the translation of TTR mRNA in a rabbit reticulocyte lysate cell-free system. After pre-incubation at 37°C for 3 h with a mRNA-to-reagent ratio of 1:4, it reduces the TTR protein level by 62%^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

950.95

C₅₀H₄₆N₈O₁₂

476667-31-9

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Pradeep SP, et al. Enhancing RNA inhibitory activity using clamp-G-modified nucleobases. Cell Rep Phys Sci. 2024;5(8):102120.  [Content Brief]

  [2]. Das A, et al. Synthesis and Biophysical Studies of High-Affinity Morpholino Oligomers Containing G-Clamp Analogs. J Org Chem. 2023;88(21):15168-15175.  [Content Brief]